RECRUITING

Cannabidiol, Morphine, Pain

Talk to us

Conditions

CBDChronic Pain

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the proposed study is to investigate the interaction of cannabidiol (CBD) and morphine effects on pain sensitivity. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) present in marijuana that alters some of the effects of marijuana.

Official Title

Human Laboratory Model to Screen Drugs With Opioid Analgesic-sparing Effects: Cannabidiol/Morphine Combinations

Quick Facts

Study Start:2019-05-01
Study Completion:2025-01-26
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04030442

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants must report having smoked a cigarette (nicotine or marijuana) AND having taken an opioid on 3 or more occasions in their lifetime.
  2. * Participants must be in good health to participate; those with certain contraindications will be excluded.
  3. * All participants will undergo psychiatric evaluation and will be asked to report their substance use history by interview and structured questionnaire methods.
  4. * Participants will undergo medical evaluations using medical history, physical exam, standard lab tests (complete blood chemistry, urinalysis, urine pregnancy test for females), and 12-lead ECG.
  1. * Serious psychiatric illness (e.g. psychotic or bipolar disorder, recent suicide attempts; severe depression)
  2. * Substance Use Disorders other than Nicotine Use Disorder and Mild Cannabis Use Disorder
  3. * Neurological diseases; cardiovascular problems (e.g. systolic BP \>140 or \<95 mmHg, diastolic BP \>90 mmHg, abnormal ECG); pulmonary diseases; systemic diseases (e.g. liver, renal, inflammatory)
  4. * Cognitive impairment (\<80 IQ)
  5. * Past-month medications that increase study risk
  6. * Women who are pregnant (urine HCG), lactating (self-report), or if heterosexually active and not using (self-report) medically approved birth control (oral or depot contraception, IUD, condom/foam, sterilization, tubal ligation)
  7. * Individuals unable to give informed consent will be excluded.

Contacts and Locations

Study Contact

Leslie Lundahl, Ph.D
CONTACT
(313)993-3960
llundahl@med.wayne.edu
Nareen Sadik, B.S
CONTACT
313-993-3960
fw6362@wayne.edu

Principal Investigator

Leslie Lundahl, PhD
PRINCIPAL_INVESTIGATOR
Wayne State University

Study Locations (Sites)

Tolan Park Medical Building
Detroit, Michigan, 48201
United States

Collaborators and Investigators

Sponsor: Wayne State University

  • Leslie Lundahl, PhD, PRINCIPAL_INVESTIGATOR, Wayne State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-05-01
Study Completion Date2025-01-26

Study Record Updates

Study Start Date2019-05-01
Study Completion Date2025-01-26

Terms related to this study

Additional Relevant MeSH Terms

  • CBD
  • Chronic Pain